[Biolojic in GlobeNewswire] Biolojic Design announces that Nektar Therapeutics has exercised its license option to develop an AI-designed agonistic antibody targeting TNFR2 for the treatment of autoimmune diseases

TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) — Biolojic Design, a biotechnology company that uses AI to transform antibodies into intelligent medicinal solutions, today announced that Nektar exercised its license option to develop a program resulting from the companies’ research collaboration initiated in 2021.

Read more here.